By Adriano Marchese
BeiGene said Wednesday that it has received European regulatory approval for its treatment of gastric and esophageal cancers.
The European Commission approved Tevimbra, the commercial name for Tislelizumab, in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma.
The oncology company said the approval is based on data from a recent study that met its primary endpoint, resulting in statistically significant and clinically meaningful overall survival benefits compared with placebo plus chemotherapy.
The study found that the median overall survival was for 17.2 months with Tevimbra compared with 10.6 months without.
These two forms of cancers are among the most common cancers and among the most common causes of cancer-related deaths. Nearly a million new patients were diagnosed with gastric cancer in 2022, and 660,000 deaths were reported globally, while close to a million new esophageal cancer cases are projected in 2040, an increase of nearly 60% from 2020, the company said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 27, 2024 06:30 ET (11:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。